Table 2.
Adverse events leading to discontinuation of bevacizumab (≥2% incidence)
| Adverse event | EB patients (n = 75) | Median time to bevacizumab discontinuation (months) |
|---|---|---|
| Any event | 32 (42.7) | 8.2 |
| Proteinuria | 12 (16.0) | – |
| Epistaxis | 3 (4.0) | – |
| Hypertension | 2 (2.7) | – |
| Hemorrhoidal hemorrhage | 2 (2.7) | – |
Data are presented as n (%)
EB erlotinib plus bevacizumab